<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2866">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338958</url>
  </required_header>
  <id_info>
    <org_study_id>RuxCoFlam</org_study_id>
    <nct_id>NCT04338958</nct_id>
  </id_info>
  <brief_title>Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation</brief_title>
  <acronym>RuxCoFlam</acronym>
  <official_title>A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RuxCoFlam is a single arm, non-randomized open phase II trial for front line treatment of&#xD;
      Covid-19 patients with defined hyperinflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RuxCoFlam is a single arm, non-randomized open phase II trial for front line treatment of&#xD;
      Covid-19 patients with defined hyperinflammation. Purpose of the study is the reversal of&#xD;
      hyperinflammation to improve pulmonary function, reduce respiratory dependency and reduce&#xD;
      mortality. Patients with a hyperinflammation Score 10/16 without a clinical diagnosis of&#xD;
      sepsis will be treated with 2 x 10mg Ruxolitinib with defined response adapted dose&#xD;
      escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response&#xD;
      assessment. Inflammation assessment will be performed every other day (day 3, 5,7) using the&#xD;
      CIS. In patients with unaffected CIS alteration &lt; 25% or increasing CIS &gt; 25% dose escalation&#xD;
      by 5mg steps (15mg, day3; 20mg day 5) at the investigator´s discretion. Treatment can be&#xD;
      extended up to 28 days if clinically indicated and the benefits of treatment outweigh the&#xD;
      risks. Primary endpoint of the study is the overall response rate in reversal of&#xD;
      hyperinflammation at day 7 compared to baseline. Secondary endpoints are total use of&#xD;
      assisted oxygenation dependency (duration (days) of invasive/non-invasive ventilation or&#xD;
      duration (days) of high-flow Oxygen support), radiologic response (reversal of pulmonary&#xD;
      Covid-signs, Lung-XRay/CT), day 15 clinical status and day 15 and day 29 mortality. Patients&#xD;
      aged ≥18 years hospitalized with COVID-19 pneumonia (demonstrated by CXRAY or chest CT), with&#xD;
      a study specific Covid Inflammation Score ≥ 10 are eligible. Patients with active&#xD;
      tuberculosis or uncontrolled bacterial, fungal, viral, or other infection (besides SARS-CoV-2&#xD;
      virus) will be excluded from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single arm, non-randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate in reversal of hyperinflammation</measure>
    <time_frame>day 7 after start of therapy</time_frame>
    <description>Patients achieving 25% reduction in hyperinflammation score (CIS) compared to baseline at day 7</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patient or guardian must provide written informed consent (and assent if&#xD;
             applicable) before any study assessment is performed.&#xD;
&#xD;
          -  2. Male and female patients aged ≥ 18 years.&#xD;
&#xD;
          -  3. Patients with temperature &gt; 37.3°C&#xD;
&#xD;
          -  4. Patients with respiratory symptoms and/or hypoxia SpO2 &lt; 93%&#xD;
&#xD;
          -  5. Patients with Covid-19 stage II and stage III&#xD;
&#xD;
          -  6. Patients with lung imaging showing bi-pulmonary infiltrates (chest X-ray or CT&#xD;
             scan).&#xD;
&#xD;
          -  7. Patients, with a Covid Inflammation Score ≥ 10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of hypersensitivity to any drugs or metabolites of similar chemical classes&#xD;
             as ruxolitinib.&#xD;
&#xD;
          -  2. Uncontrolled active bacterial, fungal, viral, or other infection (besides&#xD;
             COVID-19).&#xD;
&#xD;
          -  3. Active Tuberculosis infection.&#xD;
&#xD;
          -  4. Known Positivity for HBV, HCV or HIV.&#xD;
&#xD;
          -  5. Patients who are on long-term use of oral anti-rejection or immunomodulatory drugs&#xD;
&#xD;
          -  6. Participating in any other interventional clinical trial for COVID-19.&#xD;
&#xD;
          -  7. Treatment with cytokine-directed agents such as anti-IL6 or anti-IL1R directed&#xD;
             antibodies (i.e. tocilizumab, anakinra). Other treatment modalities used in locally&#xD;
             adapted SOPs (corticosteroids, chloroquine, hydroxychloroquine, lopinavir-ritonavir)&#xD;
             may be given with daily documentation of dose and schedule.&#xD;
&#xD;
          -  8. ALT or AST &gt; 5 x ULN detected within 24 hours at screening (according to local&#xD;
             laboratory reference ranges).&#xD;
&#xD;
          -  9. ANC &lt; 500/µL at screening (according to local laboratory reference ranges).&#xD;
&#xD;
          -  10. Platelet count &lt; 50,000/µL at screening (according to local laboratory reference&#xD;
             ranges).&#xD;
&#xD;
          -  11. Hemoglobin &lt; 6 g/dl (3.73mmol/l)&#xD;
&#xD;
          -  12. Pregnant or nursing (lactating) women.&#xD;
&#xD;
          -  13. Female patients of childbearing potential (e.g. are menstruating) and male&#xD;
             patients who do not agree to abstinence or, if sexually active, do not agree to the&#xD;
             use of highly effective contraception as defined below, throughout the study and for&#xD;
             up to 90 days after stopping treatment, OR Female patients of child-bearing potential,&#xD;
             defined as all women physiologically capable of becoming pregnant, unless they are&#xD;
             using highly effective methods of contraception as defined below, throughout the study&#xD;
             and for up to 90 days after stopping treatment.&#xD;
&#xD;
        Highly effective contraception methods include:&#xD;
&#xD;
          -  Total abstinence (when this is in line with the preferred and usual lifestyle of the&#xD;
             patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
             post-ovulation methods) and withdrawal are not acceptable methods of contraception.&#xD;
&#xD;
          -  Female sterilization (have had surgical bilateral oophorectomy with or without&#xD;
             hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking&#xD;
             study treatment. In case of oophorectomy alone, only when the reproductive status of&#xD;
             the woman has been confirmed by follow up hormone level assessment.&#xD;
&#xD;
          -  Male sterilization (at least 6 months prior to screening). The vasectomized male&#xD;
             partner should be the sole partner for that patient.&#xD;
&#xD;
          -  Use of oral, injected or implanted hormonal methods of contraception. Placement of an&#xD;
             intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal&#xD;
             contraception that have comparable efficacy (failure rate &lt;1%), for example hormone&#xD;
             vaginal ring or transdermal hormone contraception (in case of oral contraception,&#xD;
             patients should have been using the same pill on a stable dose for a minimum of 3&#xD;
             months before Screening).&#xD;
&#xD;
        Women are considered post-menopausal and not of child bearing potential if they have had 12&#xD;
        months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age&#xD;
        appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy&#xD;
        (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks&#xD;
        ago. In the case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
        been confirmed by follow up hormone level assessment is she considered not of child bearing&#xD;
        potential.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hochhaus, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Jena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Hochhaus, Prof. Dr.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9324201</phone_ext>
    <email>ruxcoflam@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Fabisch, Dr.</last_name>
    <phone>+49 3641</phone>
    <phone_ext>9396670</phone_ext>
    <email>ruxcoflam@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen - Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justin Hasenkamp, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hochhaus, Prof. Dr.</last_name>
      <phone>+49 3641</phone>
      <phone_ext>9324201</phone_ext>
      <email>ruxcoflam@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Hochhaus, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Landeshauptstadt Stuttgart gKöR</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerald Illerhaus, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Konstanze Döhner, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul La Rosée, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Frey, PD Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Andreas Hochhaus</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

